Proactive Investors - Run By Investors For Investors

Imugene doses milestone first patient for cancer vaccine trial

The first patient was dosed in the Eastern European country of Moldova.
needle collecting vaccine from jar
The 68 patients will be studied at sites across Asia, Eastern Europe and India

Imugene Ltd (ASX:IMU) has dosed its first patient in its phase II study with its HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.

HER-Vaxx is a potentially ground-breaking cancer vaccine designed to produce an antibody response against a cancer growth signal receptor protein called HER-2.

HER-2 is found on the cell surface of multiple cancers including breast and gastric cancers.

READ: Imugene to make further cancer vaccine research presentations at AACR annual meeting

Imugene’s managing director and CEO Leslie Chong said: “There is strong medical investigator interest following the good results seen in the recently completed Phase 1b trial, where 11 out of 14 evaluable patients showed clinically meaningful responses.

“We look forward to providing regular recruitment updates as the Phase 2 study moves toward completion in 2020.”

“The start of the Phase 2 study is an important milestone for Imugene and the many medical professionals seeking treatments for patients with advanced HER-2 positive gastric cancer who often have very few medical options.”

Study being conducted in Asia, Europe and India

The Phase 2 HER-Vaxx study is designed to measure the efficacy, safety and immune response in 68 patients with metastatic gastric cancer overexpressing the HER-2 protein.

The study is randomised into two arms of either HER-Vaxx plus standard-of-care chemotherapy or standard-of-care alone.

The primary endpoint is overall survival and secondary endpoint will be progression-free survival. Safety, tolerability and immune response will also be measured.

The Phase 2 trial is being conducted at multiple sites across Asia, Eastern Europe and India.

Patients in these areas have difficulty accessing approved antibody treatments such as Herceptinâ and Perjetaâ marketed by Swiss multinational Roche Holding AG.

There is also a high prevalence of gastric cancer in the countries selected.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

Cancer cells
February 13 2019
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise
Artificial intelligence
October 29 2018
E-therapeutics believes it is now focused on the right activities
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use